TrialLancet (London, England)2025

Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.

Bruno Sangro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.